Together these data suggest that selinexor, which does not increase basal GR activity, increases total GR levels, while DEX activates GR leading to a synergistic enhancement of GRs anti-tumor transcriptional activity and cell death. This evidence concerns the gene BCL2A1 and neoplasm.